<h4>Background</h4>Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is standard after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS); however, bleeding risk remains a major concern. The gene discussed is P2RY12; the disease is acute coronary syndrome.